Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 136 AL 150

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S.

Alzheimers Res Ther. 2020 May 14;12(1):58. doi: 10.1186/s13195-020-00614-5.

Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing

Uddin MS, Kabir MT, Jeandet P, Mathew B, Ashraf GM, Perveen A, Bin-Jumah MN, Mousa SA, Abdel-Daim MM.

Oxid Med Cell Longev. 2020 Apr 29;2020:7039138. doi: 10.1155/2020/7039138. eCollection 2020.

M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

Scarpa M, Hesse S, Bradley SJ.

Adv Pharmacol. 2020;88:277-310. doi: 10.1016/bs.apha.2019.12.003. Epub 2020 Jan 27.

The Role of Synaptic Dysfunction in Alzheimer's Disease

Pei YA, Davies J, Zhang M, Zhang HT.

J Alzheimers Dis. 2020;76(1):49-62. doi: 10.3233/JAD-191334.

Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease

Berger T, Lee H, Young AH, Aarsland D, Thuret S.

Trends Mol Med. 2020 Sep;26(9):803-818. doi: 10.1016/j.molmed.2020.03.010. Epub 2020 May 14.

Polygala tenuifolia: a source for anti-Alzheimer's disease drugs

Deng X, Zhao S, Liu X, Han L, Wang R, Hao H, Jiao Y, Han S, Bai C.

Pharm Biol. 2020 Dec;58(1):410-416. doi: 10.1080/13880209.2020.1758732.

Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease

Abou MB, Sun L, Wei H.

Curr Alzheimer Res. 2020;17(4):324-328. doi: 10.2174/1567205017666200522204722.

A Perspective on Multi-target Drugs for Alzheimer's Disease

Benek O, Korabecny J, Soukup O.

Trends Pharmacol Sci. 2020 Jul;41(7):434-445. doi: 10.1016/j.tips.2020.04.008. Epub 2020 May 21.

The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease

Shah H, Patel A, Parikh V, Nagani A, Bhimani B, Shah U, Bambharoliya T.

CNS Neurol Disord Drug Targets. 2020;19(3):184-194. doi: 10.2174/1871527319666200526144141.

Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease

Fülöp T, Munawara U, Larbi A, Desroches M, Rodrigues S, Catanzaro M, Guidolin A, Khalil A, Bernier F, Barron AE, Hirokawa K, Beauregard PB, Dumoulin D, Bellenger JP, Witkowski JM, Frost E.

CNS Drugs. 2020 Jul;34(7):673-695. doi: 10.1007/s40263-020-00737-1.

Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges

Zipfel P, Rochais C, Baranger K, Rivera S, Dallemagne P.

J Med Chem. 2020 Oct 8;63(19):10705-10725. doi: 10.1021/acs.jmedchem.0c00352. Epub 2020 Jun 10.

Editorial: Next-Generation Alzheimer's Therapeutics: Leveraging Deep Biology

Longo FM, Massa SM.

J Prev Alzheimers Dis. 2020;7(3):138-139. doi: 10.14283/jpad.2020.30.

The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer's Disease Modeling

Lee C, Willerth SM, Nygaard HB.

Prog Neurobiol. 2020 Sep;192:101804. doi: 10.1016/j.pneurobio.2020.101804. Epub 2020 May 25.

Alzheimer's Disease Therapeutic Approaches

Revi M.

Adv Exp Med Biol. 2020;1195:105-116. doi: 10.1007/978-3-030-32633-3_15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias